PBA
KYMR icon

Paradigm Biocapital Advisors’s Kymera Therapeutics KYMR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-227,034
Closed -$9.61M – 26
2022
Q1 		$9.61M Buy
227,034
+101,176
+80% +$4.27M 2.54% 18
2021
Q4 		$7.99M Buy
+125,858
New +$7.33M 2.28% 18

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paradigm Biocapital Advisors's KYMR Position: Q2 2022 in Review

Paradigm Biocapital Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2022, closing a stake of 227,034 shares — an estimated $9.61M sold.

Paradigm Biocapital Advisors first reported a position in KYMR in Q4 2021 and held it in 2 quarters. The position peaked at $9.61M in Q1 2022. 100 funds tracked by Wall St. Rank hold KYMR as of Q2 2022.

  • Paradigm Biocapital Advisors reported no remaining Kymera Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 227,034 Kymera Therapeutics shares in Q2 2022, an estimated $9.61M.
  • Paradigm Biocapital Advisors first reported a position in Kymera Therapeutics in Q4 2021 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Kymera Therapeutics position peaked at $9.61M in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.